Signal Pathways in Drug Discovery

Signaling cascades, also known as signal transduction pathways, are a series of biochemical reactions initiated in a cell by an external stimulus. They are vital communication systems within cells that transmit information from the extracellular environment to the nucleus, leading to the activation or inhibition of specific genes. These pathways encompass various molecular events, including the binding of ligands to cell surface receptors, intracellular signaling cascades, and modulation of gene expression. By manipulating signal pathways, it is possible to intervene in disease processes at the molecular level, with potential use for therapeutic breakthroughs.

Understanding and targeting signal pathways is one of the promising avenues for drug discovery [1, 2]. By deciphering these intricate networks of molecular interactions and developing compounds that modulate their activity, researchers are opening up new possibilities for curing illnesses that were once considered challenging to treat. Some diseases potentially cured or managed by drugs targeting signaling cascades include:

• Cancer: Signal pathways involved in cell growth, proliferation, and survival are frequently dysregulated in cancer. Targeting these pathways holds promise for developing novel anticancer agents that selectively inhibit tumor growth while minimizing damage to healthy cells [2-4].
• Inflammatory disorders: Inflammation is a complex biological response involved in numerous diseases, such as rheumatoid arthritis, asthma, or inflammatory bowel disease [5]. Signaling pathways associated with inflammation can be modulated to alleviate symptoms and reduce tissue damage [6-8].
• Infectious diseases: Signaling pathways play a crucial role in host-pathogen interactions. Targeting specific pathways involved in pathogen recognition, immune response modulation, or microbial virulence makes it possible to develop new strategies to combat infectious diseases [9, 10].

Overall, exploring signaling pathways has provided valuable insights into various diseases' pathogenesis and opened new perspectives for targeted therapies. For instance, aberrant activation of the PI3K/AKT/mTOR pathway (Fig. 1) is frequently observed in cancer cells (Fig. 2), promoting uncontrolled growth and survival [4, 11]. By designing drugs that specifically target and disrupt this pathway, researchers aim to inhibit cancer progression and improve patient outcomes. Similarly, signaling pathways associated with inflammation, neurodegenerative disorders, and cardiovascular diseases hold promise for targeted drug development.

Fig. 1. Overview of the PI3K/AKT/mTOR pathway and drug targets, adopted from [11].

Fig. 2. PI3K/Akt signaling and cancer: various biological processes are regulated by the PI3K/Akt pathway via key mediators/pathways. Adopted from [4].

Life Chemicals offers a range of screening libraries specifically designed to accelerate drug discovery efforts by studying signaling pathways. These libraries provide a diverse collection of small drug-like molecules with potential activity against various targets involved in signal cascades:

• Pathway-based Screening Librariesconsist of compounds that modulate specific signal pathways, allowing the investigation of the effects of pathway activation or inhibition in disease models.
• PI3K/Akt/mTOR Focused Library
• RAS/MAPK Signaling Pathway Focused Library
• Apoptosis Signaling Pathway Screening Library
• Anti-inflammatory Screening Compound Libraryis designed to combat inflammatory disorders and offers a comprehensive selection of compounds with anti-inflammatory properties, targeting key pathways involved in inflammation.
• Anticancer Screening Compound Librariesare tailored to target specific signaling pathways implicated in cancer development.
• Antibacterial Screening Compound Librariesaim to aid in the discovery of novel antibacterial agents, targeting among other bacterial signaling pathways.

Custom compound selection based on specific parameters can be performed on request, with competitive pricing and the most convenient terms provided.

Please, contact us at marketing@lifechemicals.com for any additional information and price quotations.

Visit our Website for a detailed product description.

Download SD files with compound structures directly from our Downloads section

References

[1] Halazy, S. (2003). Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery. Molecules 30;8(4):349–58. DOI: 10.3390/80400349. PMCID: PMC6147137.
[2] Aggarwal, B.B., Sethi, G., Baladandayuthapani, V., Krishnan, S., Shishodia, S. (2007). Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem. 15;102(3):580-92. DOI: 10.1002/jcb.21500
[3] Schweizer, L., Zhang, L. (2013). Enhancing Cancer Drug Discovery through Novel Cell Signaling Pathway Panel Strategy. Cancer Growth Metastasis 20;6:53-9. DOI: 10.4137/CGM.S11134
[4] He, Y., Sun, M.M., Zhang, G.G. et al. (2021). Targeting PI3K/Akt signal transduction for cancer therapy. Sig Transduct Target Ther 6, 425. DOI: 10.1038/s41392-021-00828-5
[5] Roy, P.K., Rashid, F., Bragg, J., Ibdah, J.A. (2008). Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol. 14;14(2):200-2. DOI: 10.3748/wjg.14.200
[6] Tas, S., Remans, P., Reedquist, K., Tak, P. (2005). Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy. Current Pharmaceutical Design, 11(5), 581–611. DOI: 10.2174/1381612053381918
[7] Yoshimura, A. (2006). Signal transduction of inflammatory cytokines and tumor development. Cancer Science 97(6), 439–447. DOI: 10.1111/j.1349-7006.2006.00197.x
[8] Zhao, H., Wu, L., Yan, G. et al. (2021). Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther 6, 263. DOI: 10.1038/s41392-021-00658-5
[9] Njoroge, J., Sperandio, V. (2009). Jamming bacterial communication: New approaches for the treatment of infectious diseases. EMBO Mol Med 1:201-210. DOI: 10.1002/emmm.200900032
[10] Gotoh, Y., Eguchi, Y., Watanabe, T., Okamoto, S., Doi, A., Utsumi, R. (2010). Two-component signal transduction as potential drug targets in pathogenic bacteria. Current Opinion in Microbiology, 13(2), 232-239. DOI: 10.1016/j.mib.2010.01.008
[11] Dienstmann, R., Rodon, J., Serra, V., Tabernero, J. (2014). Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol. Cancer. Ther. 13 (5): 1021–1031. DOI: 10.1158/1535-7163.MCT-13-0639